About: Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $0.63 (-2.55%)
BMEA NASDAQ Biomea Fusion Inc
Biomea Fusion Inc share price
Atividade de preço de BMEA
Último preço
$ 0,620
Variação (24h)
-0,02 USD (3,84%)
Volume
665.96K
Volume (média 4 sem.)
-
Abertura
$ 0,63
Variação do dia
$ 0,62 - $ 0,66
Fechamento anterior
$ 0,65
Último negócio
29 Oct, 8:19 pm GMT+0
Atrasado
29 Oct, 8:19 pm GMT+0
BMEA price performance
Atrasado
29 Oct, 8:19 pm GMT+0
quote.marketSignals